Editorials

Every quarter brings earnings reports, but every so often a company's results reveal something more instructive than the headline numbers suggest. Stryker's Q2 2026 10-Q filing is one such report. The sheer magnitude of its profit swing from Q1 to Q2 invites a particular kind of scrutiny: not just whether the numbers are real, but what they tell us about the underlying business and its path forward.

The headline is eye-catching. Net income leaped 71% quarter-over-quarter, from $745 million in Q1 to $1.276 billion in Q2. Revenue grew 9.4% sequentially, from $6.020 billion to $6.589 billion. Operating income more than doubled, rising from $936 million to $1.659 billion. For any investor chasing earnings surprises, this would seem like clear evidence of momentum.

But the real story lives in the margin structure. And that is where Stryker's Q2 results become genuinely interesting for a value investor.

Stryker's gross profit margin expanded sharply from Q1 to Q2. In Q1, gross profit was $3.810 billion on revenue of $6.020 billion, yielding a gross margin of 63.2%. By Q2, gross profit reached $4.498 billion on revenue of $6.589 billion, yielding a margin of 68.2%. That 500-basis-point improvement is substantial and warrants explanation.

Revenue grew by $569 million (9.4%) from Q1 to Q2. Gross profit grew by $688 million (18%). That is classic operating leverage. The revenue increase flowed disproportionately to gross profit, suggesting either better product mix, improved pricing, or manufacturing efficiency gains—or some combination of all three.

Then consider operating expenses. R&D spending rose only modestly from $413 million in Q1 to $434 million in Q2 (5.1% increase), while SG&A actually declined from $2.281 billion to $2.229 billion. That is the disciplined cost structure of a mature, well-managed company. Administrative and selling costs remained essentially flat as a percentage of revenue, while gross profit expanded. This is what operational excellence looks like in practice.

Stryker operates through two reportable segments. MedSurg and Neurotechnology, which generated $15.6 billion in 2025 (62% of net sales), encompasses surgical instruments, endoscopy systems, emergency medical equipment, minimally invasive vascular treatment, and neurosurgical products. Orthopaedics, which generated $9.5 billion in 2025 (38% of net sales), includes joint replacement implants, trauma surgery products, and the Mako robotic-assisted surgery platform.

Both segments benefit from favorable secular tailwinds. Global healthcare spending continues to rise, particularly in developed economies where surgical procedure volumes remain strong. The Mako platform, in particular, has reached meaningful scale: by end of 2025, more than one million robotic knee procedures and two million total robotic procedures had been performed globally, with Mako now available in over 45 countries. This is a business at inflection.

Orthopaedics and robotic surgery are not seasonal disasters in Q2 the way they might be in summer months when elective surgery declines. The margin expansion we see in Q2 suggests that MedSurg products—which include emergency and acute-care equipment less sensitive to seasonal patterns—may be driving disproportionate growth and capturing pricing power.

As of the 10-Q filing date in July 2026, Stryker traded at a price that reflected skepticism. Based on the latest key metrics, the stock carried a P/E multiple of 43.3x on trailing earnings, an EV/EBITDA of 23.1x, and an EV/Sales of 5.8x. The price-to-free-cash-flow multiple stood at 35.4x.

On first glance, these multiples look expensive. But context matters. Stryker grew revenue 11.2% year-over-year and posted net income growth of 8.5% year-over-year. The company generated 22.8% free-cash-flow growth, and its three-year revenue CAGR stands at 10.8%. For a company generating 2.8% free-cash-flow yield and growing free cash flow in the low-to-mid twenties, the valuation is not irrational. It is the price of quality compounding.

The earnings yield sits at 2.3%, well below historical equity market returns. But that yield is arriving alongside strong cash generation and a business showing no signs of deceleration. The question an investor faces is not whether Stryker is cheap—it is not. The question is whether the quality of growth, margin expansion, and cash generation justify the price. That is a personal hurdle-rate question.

The operative question now is whether Q2's margin expansion is repeatable. A 500-basis-point gross margin improvement from one quarter to the next is unusual and warrants scrutiny. It could reflect:

1. Product mix favorability. If higher-margin MedSurg products grew faster than lower-margin items, or if Mako procedures (which command premium pricing) ramped faster, margin expansion is real and sticky.

2. Pricing power. If Stryker successfully raised prices in Q2 relative to Q1, that is encouraging evidence of demand strength and competitive position. But pricing gains are not indefinite; they eventually face pushback from customers or market conditions.

3. Manufacturing efficiency. Cost-per-unit improvements from scale, automation, or procurement efficiency are structural and more durable. The SG&A decline alongside higher revenue suggests some of this is real.

4. Seasonal or one-time factors. Q1 is often weak for orthopaedic surgeries (post-holiday recovery, winter illness patterns). Q2 could be an artificial peak. If so, the margin expansion may not persist into Q3 and Q4.

Without access to segment-level margin data in the 10-Q, an investor cannot definitively answer this question. But the stability of R&D spending as a percent of sales and the absolute decline in SG&A are encouraging signs of structural, not transient, gains.

Underlying all of this is a simple principle: the value of a business is the present value of all the cash it will ever generate. Stryker reported 22.8% free-cash-flow growth year-over-year. That is exceptional. Over a three-year horizon, if the company can sustain mid-teens cash flow growth while maintaining a 2.8% free-cash-flow yield, the business compounds at a rate that rewards patient investors.

The company also carries a dividend yield of 0.97%, which grew 5.1% year-over-year. That signals management's confidence in cash generation and capital allocation discipline. For a company that started as a family business and has become a global medical device leader, the ability to combine growth with shareholder returns is evidence of a well-managed, cash-generative moat.

The book value per share stood at $59.91, with tangible book value negative (a result of goodwill and intangibles accumulated through acquisitions). For a capital-light, service-oriented business like Stryker, that is not concerning. What matters is return on deployed capital, not the balance-sheet composition.

Over 56,000 employees globally, with 28,000 in the United States, support a business that touches more than 150 million patients annually. That scale, combined with the innovation pipeline (Steri-Shield 8, LIFEPAK 35, Mako 4 with Q-Guidance, Mako Shoulder application all launched in 2025), suggests the company has built durable competitive advantages.

Stryker's Q2 results are a reminder that impressive earnings growth can coexist with expensive valuations. The 71% net income surge quarter-over-quarter is real. The margin expansion is real. The cash flow generation is real. But none of those facts tells an investor whether the stock is a good place to deploy capital at current prices.

What it does tell us is that the business model is working. A $122 billion market-cap company generating 11% revenue growth, 22.8% free-cash-flow growth, and expanding operating leverage deserves respect. It is the kind of company that creates wealth for long-term owners, even if it requires patience through periods of valuation contraction.

The near-term test is whether Stryker can maintain Q2's margin profile in Q3 and beyond. The medium-term test is whether the Mako platform can continue its trajectory of unit growth and procedure volume expansion. The long-term test is whether aging populations and rising healthcare spending in emerging markets will sustain the company's mid-teens growth rate for another decade.

Investors who bought Stryker at $396 in mid-2025 have seen significant losses. That is humbling. But it is also a reminder that even excellent businesses trade at prices where returns are muted or negative if you buy at peak valuations. The $326 price seen in late July 2026 is materially cheaper. Whether it is cheap enough depends on your own required return and your conviction in the company's ability to sustain growth and margin expansion through the next market cycle.

That is not a question the 10-Q answers. It is a question only the investor can answer for themselves.